Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIAMI
2023-508249-42-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute intestinal ischemia (AMI) comparing Oral gentamicin + metronidazole with Placebo (2 arms). Primary endpoint: Occurrence of intestinal necrosis or death within 30 days. Planned start Jul 2024; status: authorised.
02
Drugs
gentamicinmetronidazole
03
Conditions
acute intestinal ischemia (AMI)
Beyond the preview
Go deeper on 2023-508249-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508249-42-00.